Press Releases May 4, 2026 06:45 AM

Descartes Sets Date to Announce First Quarter Fiscal 2027 Financial Results

Descartes Systems Group Sets Date to Announce Q1 Fiscal 2027 Financial Results and Conference Call

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
DSGX

Descartes Systems Group announced it will release its first quarter fiscal 2027 financial results after market close on June 3, 2026. The company's executive management will discuss the results during a conference call and webcast on the same day. Descartes is a global leader in logistics technology, connecting shippers, carriers, and logistics providers on its Global Logistics Network to improve supply chain efficiency and compliance.

Descartes Sets Date to Announce First Quarter Fiscal 2027 Financial Results
DSGX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Descartes Systems Group plans to announce Q1 fiscal 2027 financial results on June 3, 2026.
  • An executive conference call and webcast will be held to discuss the financial results with investors.
  • Descartes specializes in logistics technology enabling real-time collaboration and compliance in supply chains worldwide.

WATERLOO, Ontario and ATLANTA, May 04, 2026 (GLOBE NEWSWIRE) -- Descartes Systems Group (TSX: DSG) (Nasdaq: DSGX), the global leader in uniting logistics-intensive businesses in commerce, is scheduled to report its first quarter fiscal 2027 financial results after market close on Wednesday, June 03, 2026.

Members of Descartes' executive management team will host a conference call to discuss the company's financial results at 5:30 p.m. ET on Wednesday, June 03, 2026. Designated numbers are +1 289 514 5100 or Toll-Free for North America at +1 800 717 1738, using conference ID 44762.

The company will simultaneously conduct an audio webcast on the Descartes website at www.descartes.com/descartes/investor-relations. A phone conference dial-in or webcast log-in is required approximately 10 minutes before the start.

Replays of the conference call will be available until Wednesday, June 10, 2026, by dialing +1 289 819 1325 or Toll-Free for North America using +1 888 660 6264 with Playback Passcode: 44762#. An archived replay of the webcast will be available at www.descartes.com/descartes/investor-relations.

About Descartes

Descartes powers more responsive, efficient, secure and sustainable international and domestic supply chains by uniting logistics-intensive businesses on its Global Logistics Network (GLN). Shippers, carriers, and logistics service providers connect and collaborate on the GLN leveraging technology, data and AI to manage last mile deliveries, domestic and international shipments, transportation rating and payment, global trade research, customs compliance and a variety of regulatory processes. Learn more about Descartes at www.descartes.com and connect with us on LinkedIn and X.

Descartes Investor Contact
Laurie McCauley
(519) 746-2969
investor@descartes.com


Risks

  • Financial results may not meet market expectations, potentially impacting stock price.
  • Dependence on global trade conditions and regulatory environments could affect business performance.
  • Technological or competitive challenges in the logistics and supply chain software sector may impact growth.

More from Press Releases

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 Jun 14, 2026 Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026